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Nuclear iASPP may facilitate prostate cancer
progression
EV Morris1,2, L Cerundolo1,2, M Lu1, C Verrill3, F Fritzsche1, MJ White1, GN Thalmann4, CS ten Donkelaar1, I Ratnayaka1, V Salter1,
FC Hamdy2, X Lu*,1 and RJ Bryant*,1,2
One of the major challenges in prostate cancer (PCa) research is the identification of key players that control the progression of
primary cancers to invasive and metastatic disease. The majority of metastatic PCa express wild-type p53, whereas loss of p63
expression, a p53 family member, is a common event. Here we identify inhibitor of apoptosis-stimulating protein of p53 (iASPP), a
common cellular regulator of p53 and p63, as an important player of PCa progression. Detailed analysis of the prostate epithelium
of iASPP transgenic mice, iASPPΔ8/Δ8 mice, revealed that iASPP deficiency resulted in a reduction in the number of p63 expressing
basal epithelial cells compared with that seen in wild-type mice. Nuclear and cytoplasmic iASPP expression was greater in PCa
samples compared with benign epithelium. Importantly nuclear iASPP associated with p53 accumulation in vitro and in vivo. A pair
of isogenic primary and metastatic PCa cell lines revealed that nuclear iASPP is enriched in the highly metastatic PCa cells. Nuclear
iASPP is often detected in PCa cells located at the invasive leading edge in vivo. Increased iASPP expression associated with
metastatic disease and PCa-specific death in a clinical cohort with long-term follow-up. These results suggest that iASPP function
is required to maintain the expression of p63 in normal basal prostate epithelium, and nuclear iASPP may inactivate p53 function
and facilitate PCa progression. Thus iASPP expression may act as a predictive marker of PCa progression.
Cell Death and Disease (2014) 5, e1492; doi:10.1038/cddis.2014.442; published online 23 October 2014
Prostate cancer (PCa) is the commonest male malignancy
and second leading cause of male cancer-related death in the
Western world. As metastatic PCa can kill patients it is
important to understand the molecular switches responsible
for progression of localised disease to an invasive and
metastatic phenotype.
Mutation of the tumour suppressor gene p53, one of the
commonest mutated genes in human cancers,1 is associated
with invasive metastatic PCa. p53 mutation or loss-of-
heterozygosity rates in early PCa are low,2–6 suggesting p53
mutation is a late event in PCa and that selection for loss of
p53 function occurs during PCa progression.7–15 Mutant p53
can induce cancer cell invasion by binding to p63 and
inhibiting its transcriptional activity.16–19 p63 is a member of
the p53 family and shares high sequence similarity to p53 at its
DNA binding domain. p63 is predominantly expressed in basal
epithelial cells and is a master transcription factor that
determines epithelial stratification. There are six p63 isoforms
and TAp63α, β and γ contain different lengths of C terminus,
whereas ΔNp63α, ΔNp63β and ΔNp63γ lack the N-terminal
transactivation domain. p63 is expressed in the basal cells of
normal adult prostate epithelium20 with ΔNp63α being the
most prominent isoform.21 ΔNp63-positive cells of the
urogenital sinus can generate all prostate epithelial cell
lineages in mice,22 suggesting that these are stem/progenitor
cells. Loss of the p63-expressing basal cell layer is a hallmark
of invasive PCa.21,23,24 Mutant p53 is mainly detected in
metastatic PCa cells, therefore it is unlikely that mutant p53
induces PCa cellular invasiveness by inhibiting p63 function.
In addition, as p53 mutations or copy number loss are
detected in only 25%2 of metastatic PCa, it is likely that p53
loses its tumour suppressor function in metastatic disease
through other means. Cellular regulators of p53 may be
responsible for the inactivation of p53.
Increased expression of two p53 inhibitors, mouse double
minute 2 homologue and inhibitor of apoptosis-stimulating
protein of p53 (iASPP), is responsible for the inactivation of
wild-type p53 in human malignant melanoma25 which, like
PCa, has a low rate of p53 mutation. iASPP belongs to
the ASPP family of proteins that comprise iASPP, ASPP1
and ASPP2. ASPP1 and ASPP2 were originally identified as
activators, and iASPP as an inhibitor, of p53-mediated
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apoptosis.26,27 Studies have demonstrated that ASPP2
is a haploinsufficient tumour suppressor,28–30 and ASPP1
and ASPP2 cooperate with oncogenic RAS to potentiate RAS
signalling.31–33 ASPP2 can exert its tumour suppressor
function by mediating RAS-induced cellular senescence and
by inhibiting RAS-induced autophagy in primary cells.31,33
ASPP2 also increases RAS-induced p53-mediated transcrip-
tion and apoptosis in cancer cells.32 In normal epithelial cells,
ASPP2 can bind and colocalise with protease activated
receptor 3 thereby maintaining the integrity of cell polarity
and adherence junctions.34,35 ASPP2 is a novel suppressor of
squamous cell carcinoma through its ability to repress ΔNp63
expression via a nuclear factor kappa-light-chain-enhancer of
activated B cells-mediated pathway.30 iASPP is thought to
function as an oncoprotein as it is over-expressed in several
malignancies36–39 including a small cohort of PCa cases.40
Consistent with this, iASPP is highly expressed in basal
epithelial cells and its expression level decreases upon
cellular differentiation in vitro and in vivo.30,41 iASPP is an
inhibitor of cellular senescence and iASPP deficiency accel-
erates differentiation of keratinocytes in vitro and in vivo, partly
through iASPP’s ability to bind and regulate p63 function.41,42
These observations are in agreement with in vivo findings that
iASPPand ASPP2 are key regulators of epithelial stratification
with opposing functions, partly through their ability to exert
opposing regulation of p63 expression and activity.30,41,42 We
recently showed that ASPP2 represses ΔNp63 expression30
whilst iASPP is known to induce p63 expression in
keratinocytes,42 and we also showed that iASPP binds
p63 and regulates its transcriptional activity to suppress
cellular senescence and differentiation.41 Since p63 is
required for mouse prostate development and its expression
is lost in invasive PCa, we investigated whether iASPP plays a
role in mouse prostate development through its ability to
regulate p63. The potential role of iASPP in regulating the
behaviour of p63-negative PCa cells was also investigated in
PCa samples.
Results
iASPP deficiency causes a reduced number of
p63-expressing basal cells and increased expression of
differentiation markers. To investigate the effect of iASPP
Figure 1 Phenotypic analysis of iASPPΔ8/Δ8 mouse prostates. (a) The prostate glands of iASPPΔ8/Δ8 mice were macroscopically similar to those of wild-type mice.
(b) iASPPΔ8/Δ8 mouse prostate lobes developed with an intact epithelial lining and a lumen. (c) iASPPΔ8/Δ8 mouse (n= 3) prostate lobes demonstrated a small reduction in the
number of Ki67-positive actively proliferating epithelial cells compared with iASPP+/+ (n= 3) controls. (d) iASPPΔ8/Δ8 (n= 4) mice demonstrated a small reduction in the number
of BrdU-labelled cells in each lobe of the prostate following BrdU injection compared with iASPP+/+ (n= 3) controls. (e) iASPPΔ8/Δ8 mice (n= 5) demonstrated a small reduction
in the number of TUNEL-positive apoptotic epithelial cells in each lobe of the prostate compared with iASPP+/+ (n= 5) controls. (f) iASPPΔ8/Δ8 mice (n= 5) had significantly fewer
p63-positive basal epithelial cells compared with iASPP+/+ mice (n= 5). The expression level of TP63 in prostate protein extracts from iASPPΔ8/Δ8 mice was diminished
compared with iASPP+/+ controls
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loss on gross prostate morphology the prostate glands
from iASPPΔ8/Δ8 mice were analysed macroscopically.
The prostate gland lobes of iASPPΔ8/Δ8 mice were some-
times smaller than those of age-matched wild-type mice but
were not significantly smaller across the cohort (P40.05)
(Figure 1a). There was no difference in overall size of these
animals. The prostate lobes of iASPPΔ8/Δ8 mice had an
epithelial cell layer and a lumen with similar haematoxylin and
eosin (H&E) appearances to wild-type (Figure 1b). These
results suggest that iASPP deficiency is unlikely to grossly
affect mouse prostate development.
We showed previously that iASPP inhibits apoptosis and
cellular senescence, therefore we tested whether iASPP
deficiency enhances apoptosis or inhibits cellular proliferation,
and we observed a small reduction in the number of
Ki67-expressing cells in iASPPΔ8/Δ8 mice compared with
wild-type (Figure 1c). iASPPΔ8/Δ8 mice demonstrated a small
reduction in the number of bromodeoxyuridine (BrdU)-labelled
cells in all prostate lobes compared with wild-type (Figure 1d).
Similar number of apoptotic prostate epithelial cells were
observed in iASPPΔ8/Δ8 mice compared with wild-type
(Figure 1e). These results suggest that iASPP loss does
not enhance apoptosis but reduces cellular proliferation in the
mouse prostate.
iASPP has recently been found to be highly expressed in the
nucleus of basal cells where it interacts with TP63, and its
Figure 1 Continued
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expression becomes cytoplasmic in differentiated cells.41,42
We observed that iASPP was expressed in both the
TP63-positive basal cell layer and the TP63-negative luminal
cell layer (Supplementary Figure 1A) of mouse prostate
epithelium. Both cytoplasmic and nuclear iASPP expression
accordswith previous studies.43 The iASPP staining is specific
and is confirmed by absence of signal in iASPPΔ8/Δ8 mice
(Supplementary Figure 1B). We observed a significant
decrease in the number of p63-expressing epithelial cells in
all lobes of iASPPΔ8/Δ8 mouse prostates compared with wild-
type (Figure 1f).
Since p63-expressing cells are progenitors and iASPP
deficiency is known to facilitate keratinocyte differentiation, the
effects of loss of iASPP function on prostate epithelial cell
differentiation were investigated. The prostate mainly consists
of basal and luminal cells, and a small subpopulation of
neuroendocrine cells.44 Although the basal and luminal cells
are discrete populations, intermediate cells express a mixture
of basal and luminal markers45–48 and are thought to have
entered the differentiation programme and be transitional
between basal and luminal phenotypes. The cytokeratin (Ck)
expression pattern can be used to distinguish between these
three populations of cells. In prostate epithelium, basal cells
express Ck5 and Ck14, luminal cells express Ck8 and Ck18
and intermediate cells express basal and luminal Cks and
Ck19. Basal and luminal cells were present in iASPP-deficient
mice as demonstrated by Ck5 and Ck8 IF (Supplementary
Figure 1C). To determine the levels of Ck expression, protein
was extracted from prostate tissue from three iASPPΔ8/Δ8 and
three age-matched wild-type mice. We observed an increase
in Ck19 expression in iASPPΔ8/Δ8 compared with wild-type
prostate (Supplementary Figure 1D) with minimal changes in
Ck5 and Ck8 expression. These results suggest that iASPP
deficiency facilitates p63-expressing progenitors to commit to
the luminal cell linage by transitioning into intermediate cells,
and that iASPP regulates mouse prostate development
through its ability to inhibit cellular senescence and prostate
epithelium differentiation. The findings that iASPP is
expressed in both basal and luminal prostate epithelial cells
suggest that iASPPmay affect prostate epithelial cell functions
through p63-dependent and -independent pathways.
iASPP is expressed in human prostate epithelium
and nuclear iASPP associates with invasive phenotypes.
To investigate whether iASPP plays a role in human PCa we
first examined iASPP expression pattern in a number of
benign prostate samples using an anti-iASPP mouse mono-
clonal antibody LX049.341 to carry out IHC staining. We
observed that iASPP was predominantly expressed in the
nucleus and cytoplasm of p63-positive basal cells in benign
prostate epithelium. Occasional low levels of iASPP expres-
sion were also observed in benign luminal epithelial cells
Figure 2 iASPP expression differs between benign and malignant human prostate epithelium. (a) iASPP is mainly expressed in the nucleus and cytoplasm of p63-positive
basal cells, and to a lesser extent in the nucleus of luminal epithelial cells, in benign human prostate epithelium. Nuclear (P= 0.002) and cytoplasmic (P= 0.01) iASPPexpression
is increased in human prostate cancer samples compared with benign epithelial cell samples. (b) Nuclear iASPPexpression was greater in prostate cancer cells invading through
the capsule in locally invasive pT3a disease compared with areas of intra-prostatic tumour or benign prostate epithelium
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(Figure 2a). We noticed that the benign epithelium adjacent to
areas of PCa expressed significantly greater levels of iASPP
than benign prostate epithelium samples taken from men
without PCa (Supplementary Figure 2A). Consistent with this
an increase in both cytoplasmic and nuclear iASPP expres-
sion was observed in PCa samples in comparison to benign
prostate epithelium (Figure 2a). By analysing iASPP expres-
sion in PCa cells with different invasive properties within
locally advanced cases, we observed that nuclear (Figure 2b)
and cytoplasmic (Supplementary Figure 2B) iASPP expres-
sion was significantly greater in cells at the ‘leading edge’
invading the prostate capsule compared with cancer cells
within intra-prostatic tumour. These results suggest that
iASPP expression patterns differ in PCa cells. High levels
of nuclear and cytoplasmic iASPP associates with PCa cells
with an invasive property, whereas low iASPP-expressing
PCa cells are confined to the gland and are not invading
locally.
Slow migrating nuclear iASPP is enriched in metastatic
PCa cells. N-terminal phosphorylation of iASPP retards its
migration in sodium dodecyl sulfate (SDS) gel and causes
nuclear accumulation in cells,25 and nuclear iASPP localisa-
tion is associated with human melanoma metastasis.25 The
observation that nuclear iASPP is enriched in PCa cells with
invasive properties led us to test the hypothesis that iASPP
phosphorylation may be enhanced in metastatic PCa cells
in vitro using a pair of isogenic LNCaP cell lines. LNCaP-LN3
is a metastatic derivative of LNCaP cells. Using IF we
observed that p53-null PC3 cells and p53-mutant (P233L and
V274F) DU145 cells49 expressed predominantly cytoplasmic
iASPP. In wild-type p53-expressing LNCaP cells, iASPP is
expressed with a relatively equal distribution between
nucleus and cytoplasm, whereas LNCaP-LN3 derivatives
expressed predominantly nuclear iASPP (Figure 3a). iASPP
migrated as two bands in WBs of these PCa cell lines
however the proportion of slow-migrating iASPP was highest
in LNCaP-LN3 cells corresponding with the enrichment of
modified nuclear iASPP in these cells. LNCaP cells
expressed both slow- and fast-migrating iASPP with similar
intensity and this expression pattern correlates with the
roughly equal cellular distribution of iASPP detected in these
cells. PC3 and DU145 cells expressed predominantly
fast-migrating unmodified cytoplasmic iASPP (Figure 3b).
The slower migrating modified iASPP band is primarily
detected in nuclear protein extracts, whereas the faster
migrating unmodified iASPP band is localised primarily to the
cytoplasm (Figure 3c). LNCaP-LN3 cells expressed a greater
proportion of modified nuclear iASPP than LNCaP cells.
These results illustrate that modified nuclear iASPP is
enriched in PCa cells with high metastatic potential.
Increased nuclear iASPP expression correlates with
TP53 accumulation in vivo and in organotypical
co-cultures in vitro. p53 mutation is a late event in PCa
progression. High levels of TP53 expression is often
associated with p53 mutation and is detected in invasive
metastatic PCa cells. In our tissue microarray (TMA) cohort of
PCa samples we only detected high levels of TP53
expression (430% of cancer cell nuclei14) in 5/200 PCa
samples. We observed that nuclear iASPP expression was
significantly higher in samples strongly expressing TP53
compared with samples with absent or weak TP53 expres-
sion (Figure 4a). High levels of TP53 expression were
detected within cells at the ‘leading edge’ of locally invasive
PCa compared with intraprostatic tumour cells. Higher levels
of nuclear TP53 expression were detected in locally
advanced PCa cases compared with organ-confined tumours
(Figure 4b). These results suggest a potential association
between high levels of TP53 and nuclear iASPP accumula-
tion in the leading edge of locally invasive PCa.
This hypothesis was tested by performing an in vitro
organotypic co-culture using DU145 cells known to harbour
mutant p5349 and express high levels of TP53, which
accumulates in the nucleus. Using double IF staining we
observed that some DU145 cells with accumulated TP53 also
expressed nuclear iASPP (Figure 4c). DU145 cells with co-
localisation of iASPP and TP53 were preferentially seen at the
‘leading edge’ of the layer of cells within the organotypic co-
cultures. This contrasts with observations in organotypic co-
cultures of PC3 cells which do not express TP53, and LNCaP
and LNCaP-LN3 cells expressing wild-type TP53. The associa-
tion between nuclear TP53 and nuclear iASPP accumulation in
organotypical co-cultures of DU145 cells suggests that mutant
TP53 may interact with nuclear iASPP. Using an immunopre-
cipitation assay we observed that an anti-iASPP antibody was
able to co-immuno-precipitate TP53 with iASPP in DU145 cell
lysates (Figure 4d). These results suggest an association
between the accumulation of mutant TP53 and nuclear iASPP,
and that mutant TP53 is able to bind iASPP in vitro.
Increased iASPP expression in PCa is associated with an
adverse clinical outcome. We investigated whether the
increased iASPP expression observed in PCa samples might
have prognostic clinical significance using a TMA of samples
from 203 patients undergoing radical prostatectomy with
prolonged clinical follow-up50 (Table 1). Increased iASPP
expression was associated with an adverse clinical outcome.
Increased nuclear iASPP expression in intermediate grade
(Gleason sum score 7) PCa was significantly associated with
PCa-specific death. Increased cytoplasmic iASPP expression
in high grade (Gleason sum score ≥8) PCa was associated
with both metastasis formation and PCa-specific death
(Figure 5a). The prognostic significance of tumour stage,
pre-operative prostate-specific antigen level, and nuclear and
cytoplasmic iASPP expression were tested in a Cox regres-
sion multivariate analysis (Table 2). Nuclear iASPP expres-
sion in Gleason 7 tumours was prognostic for PCa-specific
death, whilst cytoplasmic iASPP in high-grade (Gleason ≥ 8)
tumours was prognostic for the development of bone
metastases and PCa-specific death.
Increased nuclear iASPP expression was associated with
an increased risk of PCa-specific death in patients with locally
advanced PCa undergoing radical prostatectomy, whereas
this association was not seen in organ-confined disease
(Figure 5b). These results suggest that increased expression
of nuclear and cytoplasmic iASPP has clinical significance by
conferring an increased risk of developing metastases or
resultant PCa-specific death following treatment of early
disease.
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Discussion
The transcription factor p63 is specifically expressed in
prostate basal epithelial cells21,51–53 and altered p63
expression is utilised in PCa diagnosis.20,21,23,54,55 A ‘Pros-
tate-63 Cancer Diagnostic Test’ has been approved by the US
Food and Drug Administration (FDA) as a diagnostic marker
of PCa in clinical samples. In agreement with the importance
Figure 3 Phosphorylated iASPP accumulates in the nucleus of prostate cancer cells. (a) Highly metastatic LNCaP-LN3 prostate cancer cells expressed predominantly
nuclear iASPP, whereas LNCaP cells with lower metastatic potential expressed iASPP with a relatively equal distribution between nucleus and cytoplasm. The p53-null PC3 cell
line and p53-mutant (P233L and V274F) DU145 cell line expressed predominantly cytoplasmic iASPP. (b) iASPP migrated as two bands in an immunoblot of whole-cell protein
extracts from prostate cancer cells. LNCaP-LN3 cells predominantly expressed the slower migrating iASPP band previously identified as being nuclear localised phosphorylated
iASPP. LNCaP cells expressed both slow- and fast-migrating iASPP, corresponding with its roughly equal subcellular distribution. PC3 and DU145 cells, which exhibited
predominantly cytoplasmic localised iASPP, expressed predominantly fast-migrating unmodified cytoplasmic iASPP. (c) The slower migrating modified iASPP band is primarily
detected in nuclear protein extracts, whereas the faster migrating unmodified iASPP band is localised primarily to the cytoplasm. Invasive metastatic LNCaP-LN3 cells express a
greater proportion of modified nuclear iASPP than non-invasive LNCaP cells
iASPP promotes prostate cancer progression
EV Morris et al
6
Cell Death and Disease
Figure 4 Nuclear iASPP expression was increased in prostate cancer samples with a high level of TP53 expression. (a) iASPPexpression in human prostate cancer samples
was greater in both wild-type p53 (o30% nuclei expressing TP53) and mutant p53 (430% nuclei expressing TP53) samples compared with benign prostate epithelium
(Po0.05). Although the number of mutant p53 prostate cancer samples was small (n= 5) compared with the number of wild-type p53 samples (n= 195) we observed that the
nuclear iASPP expression was higher in mutant p53 samples compared with wild-type p53 samples. (b) TP53 and iASPP expression in cells within the leading edge of locally
invading pT3a prostate cancer was compared with other areas of the sample. TP53 expression was greatest in invading prostate cancer cells within the leading edge. iASPP
expression was higher in prostate cancer cells with high TP53 expression, compared with cancer cells with low TP53 expression, in capsular-invading and intra-prostatic areas of
tumour. Arrow depicts direction of invasion into the prostate capsule. (c) Nuclear iASPP is co-expressed with nuclear TP53 in DU145 prostate cancer cells at the invasive margin
in organotypic co-cultures. (d) Immunoprecipitation of TP53 probed with anti-iASPP and anti-TP53 antibodies demonstrated that iASPP interacts with mutant TP53
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of p63 in the tumorigenesis of PCa, transgenic mouse studies
have established a crucial role for p63 in the development of
the mouse prostate gland. We show here for the first time that
iASPP, a cellular regulator of p63, also plays a role in the
normal development of the mouse prostate gland. We
observed a detectable reduction in the number of proliferating
cells in iASPPΔ8/Δ8 mouse prostate compared with wild-type
mice. Interestingly, we observed significantly fewer TP63-
expressing basal cells within the prostate epithelium of
iASPPΔ8/Δ8 compared with wild-type mice, suggesting iASPP
may be required to maintain the TP63-positive basal cell layer.
Consistent with a role for iASPP in suppressing epithelial
differentiation, we observed an increase in the expression
level of Ck19, a marker of intermediate prostate epithelial
cells,47,56 in iASPPΔ8/Δ8 mouse prostates. Cells which are
phenotypically intermediate between basal and secretory
cells have been found to be enriched in proliferative
inflammatory atrophy lesions of the prostate, suggesting
that these cells may be implicit in PCa.57 Our observations
in iASPPΔ8/Δ8 mouse prostate epithelium are in complete
agreement with previous findings whereby iASPP inhibits
cellular senescence and binds and regulates p63 function
in maintaining homeostasis of stratified epithelium in
mouse skin and oesophagus.41,42 An increased differentiation
process caused by iASPP deletion may accelerate
the rate of commitment of p63-expressing progenitors to
trans-differentiate into luminal epithelial cells via intermediate
cells. In turn this could result in an enhanced diminishment of
prostate progenitors.
Figure 4 Continued
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We observed that loss of iASPP function results in a
reduced number of p63 expressing basal cells in prostate
epithelium. It has recently been shown that iASPP can
regulate p63 expression via a microRNA autoregulatory
feedback loop.42 It has also been demonstrated that iASPP
binds p63 and directly regulates its activity. Importantly iASPP
is able to inhibit cellular senescence and epithelial cell
differentiation.41
It is possible that absence of iASPP induces basal prostate
epithelial cells to undergo differentiation due to iASPP's ability
to regulate p63 activity and maintain the proliferative potential
of basal epithelial cells. Future studies are needed to under-
stand how iASPP deficiency causes a reduction in p63
expressing prostate epithelial basal cells. Regardless of this
our observation that nuclear iASPPexpression was increased
in PCa progression was interesting given that the expression
of TP63 is frequently lost in PCa.24 It is known that p63
expression defines the basal epithelial cell lineage, and we
speculate that when PCa cells enter their metastatic phase
there is possible cellular reprogramming, lineage change and
an epithelial-to-mesenchymal transition (EMT). p63 is known
to regulate key epithelial proteins such as cadherins and cell
adhesion molecules.58 Moreover, p53 is an important inhibitor
of EMT59 and most PCa express wild-type p53.2–6 Therefore
an inhibitor of p53 such as iASPP could play an important role
in facilitating prostate epithelial cells to undergo EMT.
We showed recently that nuclear iASPP has the highest p53
binding and p53 inhibition potency.25 It is perhaps via this
mechanism that nuclear iASPP contributes to loss of p53
function, induction of EMT, loss of the epithelial cell lineage
Figure 4 Continued
Table 1 Clinical characteristics of the radical retropubic prostatectomy tissue
microarray cohort
Radical retropubic
prostatectomy
(n=203)
n (%)
Median age (range) 63 (range 44–75) years
Preoperative PSA
≤10 79 (38.9)
10.1–20 59 (29.1)
420 64 (31.5)
Unknown 1
pT-stage
≤pT2 94 (46.3)
≥pT3 109 (53.7)
pN-stage
pN0 143 (70.4)
pN1 52 (25.6)
pN2 6 (3.0)
Unknown 2
Gleason grade
≤6 137 (67.5)
7 36 (17.7)
≥8 29 (14.3)
Unknown 1
Median FU (range), years 8.8 (0.1–17.7)
Developed bone metastases at
10 years
43 (21.2)
Prostate cancer-specific death
at 10 years
37 (18.2)
Abbreviations: FU, follow-up; PSA, prostate-specific antigen
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Figure 5 Increased iASPP expression in prostate cancer samples is associated with an adverse clinical prognosis. (a) Increased nuclear iASPP expression in intermediate
grade (Gleason sum score 7) prostate cancers was associated with increased prostate cancer-specific death after 10 years of follow-up following radical surgery. Increased
cytoplasmic iASPP in high grade (Gleason sum score≥ 8) prostate cancer samples was associated with an increased risk of both prostate cancer bone metastasis development
and prostate cancer-specific death after 10 years of follow-up following radical surgery. (b) Increased nuclear iASPP expression was associated with a poor clinical outcome in
men treated surgically for non organ-confined (≥ pT3a) prostate cancer. High nuclear iASPP in this group of patients was associated with an increased risk of prostate cancer-
specific death following radical surgery
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and concomitant loss of p63 expression. This hypothesis
warrants further investigation.
The observation that iASPP is predominantly expressed in
the nucleus, and to a lesser degree in the cytoplasm of basal
prostate epithelial cells in benign prostate samples, suggests
that iASPP may maintain the proliferative potential of basal
epithelial cells. The finding that iASPP co-localises with TP63
within the nucleus of benign prostate epithelial cells agrees
with previous findings where iASPP binds and directly
regulates TP63 function.41 We observed that iASPP expres-
sion was increased in the nucleus and cytoplasm of PCa
cells in a cohort of over 200 PCa samples compared with
benign prostate epithelial samples. This agrees with an
oncogenic role for iASPP in PCa development. It is also
in agreement with numerous findings showing an increase in
iASPP expression in human cervical, head and neck, ovarian,
melanoma and a small cohort of PCa samples.25,39,40,60,61 To
date, however, changes in iASPP expression have not been
associated with long-term prognosis in PCa. Our detailed
analysis of iASPP expression patterns in a cohort of 61 PCa
samples containing benign prostate epithelial cells adjacent to
areas of cancer allowed us for the first time to obtain evidence
of a potential ‘field change effect’ of iASPP expression. iASPP
expression levels in the histologically normal prostate directly
adjacent to cancer were seen to be significantly greater than
benign epithelium in men without PCa. This observation is in
keeping with other published reports, suggesting that a ‘field
change’ phenomenon or ‘field cancerisation’ effect exists
during malignant transformation of prostate epithelium.62–70
Furthermore we observed that nuclear iASPP is enriched
within PCa cells at the invasive front of locally invading
tumours in vivo, and within the experimentally derived
metastatic PCa cell line LNCaP-LN3 compared with parental
LNCaP cells in vitro. Interestingly, LNCaP cells contain
wild-type p53 and the majority of human PCa also express
wild-type p53 with this gene only mutated or deleted in ~ 30%
of the cases. Our findings concur with those in a recent study
showing a nuclear enrichment of iASPP in malignant meta-
static human melanoma cells,25 and this is interesting given
that both melanoma and PCa generally have a lower rate of
p53 mutation than many other cancer types.
We observed that cytoplasmic iASPP expression, in
addition to nuclear iASPP, is detected in PCa samples, and
increased cytoplasmic iASPP was associated with an
increased risk of both metastasis formation and PCa-specific
death following radical surgery. We do not currently under-
stand the biological importance of cytoplasmic iASPP, how-
ever p53 has previously been detected in the cytoplasm as
well as the nucleus of cells, and levels of cytoplasmic iASPP
expression have been associated with an adverse prognosis
in other cancer types.39 It is possible that cytoplasmic iASPP
may inhibit the activity of cytoplasmic p53, although it is known
that nuclear iASPP has a higher binding affinity to p53.25
Cytoplasmic iASPP may influence aspects of p53 function
independent of its transcriptional activity, however further
studies will be necessary to fully elucidate the biological role of
cytoplasmic iASPP.
These findings suggest that changes in iASPP expression
and subcellular localisation may potentially be useful clinically
as a biomarker predictive of clinically aggressive PCa. The
results of this study identify iASPP as being a key molecular
switch in the progression of PCa to an invasive and metastatic
phenotype with a lethal outcome.
Materials and Methods
Mice. The generation of iASPPΔ8/Δ8 mice has been described previously.41 All
animal procedures were approved by local ethical review and licensed by the UK
Home Office. All iASPPΔ8/Δ8 mice analysed in this study were paired with
age-matched wild-type controls and these were littermates wherever possible.
Prostate tissues were fixed in 10% buffered formalin overnight, dehydrated in an
Table 2 Multivariate analysis of clinical prognostic factors for the development of prostate cancer bone metastasis and prostate cancer-specific death in the radical
retropubic prostatectomy tissue microarray cohort
Bone metastases Prostate cancer death
HR (95% CI) P HR (95% CI) P
All prostate cancer cases
pT stage 1.92 (0.96–3.85) 0.065 4.33 (1.75–10.69) 0.001
pN stage 1.58 (0.88–2.86) 0.129 1.96 (1.05–3.67) 0.035
PSA 1.01 (0.99–1.02) 0.505 1.00 (0.99–1.02) 0.828
Gleason group 2.32 (1.55–3.47) o0.001 1.95 (1.23–3.10) 0.004
Nuclear iASPP expression 0.97 (0.47–1.98) 0.925 1.82 (0.91–3.66) 0.092
Cytoplasmic iASPP expression 0.98 (0.49–1.94) 0.948 1.26 (0.63–2.53) 0.508
Gleason 7 prostate cancer cases
pT stage 6.36 (0.91–44.28) 0.062 3.72 (0.74–18.63) 0.110
pN stage 1.18 (0.31–4.54) 0.813 1.13 (0.36–3.60) 0.833
PSA 1.04 (1.0–1.09) 0.055 0.99 (0.94–1.04) 0.576
Nuclear iASPP expression 3.81 (0.80–18.1) 0.093 3.72 (1.10–12.61) 0.035
Cytoplasmic iASPP expression 0.56 (0.11–3.0) 0.501 0.53 (0.12–2.36) 0.403
Gleason ≥8 prostate cancer cases
pT stage 3.84 (0.91–16.18) 0.066 8.20 (0.91–73.57) 0.06
pN stage 0.70 (0.19–2.53) 0.585 1.84 (0.46–7.33) 0.389
PSA 1.01 (0.99–1.03) 0.56 1.00 (0.98–1.02) 0.766
Nuclear iASPP expression 0.70 (0.16–3.13) 0.639 0.22 (0.03–1.47) 0.119
Cytoplasmic iASPP expression 4.58 (1.24–16.98) 0.023 8.17 (1.46–45.73) 0.017
Abbreviations: CI, confidence interval; HR, hazard ratio; iASPP, inhibitor of apoptosis-stimulating protein of p53; PSA, prostate-specific antigen
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ethanol series and cleared in xylene before being embedded in paraffin. The entire
prostate was embedded as a whole in a consistent manner to avoid problems with
changes in orientation of the lobes. Four micrometre sections were cut for thickness
for experimental analysis. For cell proliferation studies, mice were injected with
30 μg BrdU per gram of body weight 24 h before being killed.
Cell lines. LNCaP (May 2003), PC-3 (February 2004), and DU145 (December
2011) cells were purchased from ATCC (Manassas, VA, USA). LNCaP-LN3 cells were
a generous gift from Professor Curtis Pettaway (Department of Urology, The University
of Texas MD Anderson Cancer Center, Houston, TX, USA). These cells were
maintained in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS) (GE
Healthcare Life Sciences, Little Chalfont, UK), sodium pyruvate, MEM vitamins and
MEM non-essential amino acids (Invitrogen, Paisley, UK) and were used for no longer
than 6 months post resuscitation. Normal human fibroblast (NHF) cells were
maintained in Dulbecco’s Modified Eagle Medium (DMEM) (Invitrogen) supplemented
with 10% FCS. All cell lines were supplemented with 100 U/ml of penicillin and
streptomycin (Invitrogen) and incubated at 37 °C in a 5% CO2 atmosphere.
Organotypic culture. A suspension of 5 × 105 NHFs was prepared in DMEM
for each organotypic culture. One millilitre scaffold gel plugs were prepared for each
organotypic culture containing 5 × 105 NHFs, 10% FCS and 1 : 1 rat tail collagen
type I/Matrigel (Becton Dickinson, Oxford, UK) in DMEM, and after overnight
incubation at 37 °C, 5 × 105 PCa cells (PC3, DU145, LNCaP and LNCaP-LN3) were
plated onto the upper surface of each gel plug and incubated for a further 24 h. A
sterile nylon square in a Petri dish was covered with 250 μl gel containing 10% FCS,
70% collagen and DMEM and polymerised by incubating at 37 °C for 20 min. Ten
millilitre 1% glutaraldehyde (Sigma, Gillingham, UK) in phosphate buffered saline
(PBS) was then added to the Petri dish and the nylon sheets incubated at 4 °C for
1 h then washed in PBS followed by DMEM and then incubated at 4 °C overnight.
The nylon sheets were then mounted on metal scaffolds and placed in a Petri dish,
and the NHF/PCa cell-containing gel plugs were placed onto the nylon sheet and
incubated at 37 °C for 10 days with culture media just beneath the nylon sheet. Gels
were then formalin-fixed, processed and sectioned for histology.
Protein extracts. Protein extracts were obtained from cultured cells or
homogenised mouse prostate using urea buffer. Mouse prostate lysates were sonicated
prior to protein quantification. Protein concentrations were determined using a protein
assay reagent system (Bio-Rad, Hercules, CA, USA) and spectrophotometric analysis
at 595 nm. The absorbance of samples was compared with a standard curve derived
from known concentrations of bovine serum albumin (BSA; Sigma).
Antibodies. Primary antibodies used in this study for Western blotting (WB),
immunofluorescence (IF), and immunohistochemistry (IHC) include: rat anti-BrdU
(ab6326, IF 1 : 200); rabbit anti-Ck 19 (ab53119, WB 1 : 500); rabbit anti-Ck
5 (ab53121, WB 1 : 750, IF 1 : 3000); rabbit anti-Ck 8 (ab59400, WB 1 : 500,
IF 1 : 200); mouse anti-lamin B (ab8983, WB 1 : 1000); rabbit anti-tubulin (ab52901,
WB 1 : 2000) (Abcam, Cambridge, UK); mouse anti-iASPP (purified LX049.3, IF
1 : 250, IHC 1 : 250, WB 1 : 1000); rabbit anti-ki67 (Vector Laboratories,
Peterborough, UK; IHC 1 : 200); mouse anti-Ku80 (ThermoFisher Scientific,
Loughborough, UK; WB 1 : 2000); rabbit anti-p53 (CM1, WB 1 : 1000, IF 1:250);
mouse anti-p53 (DO-1, WB 1 : 1000); mouse anti-p63 (4A4, Santa Cruz, Dallas, TX,
USA; WB 1 : 1000; IF/IHC 1 : 200).
Secondary antibodies (Invitrogen unless stated) used in this study include: rabbit
anti-mouse horseradish peroxidase (HRP) (Dako, Ely, UK; WB 1 : 2000), swine anti-
rabbit (Dako, WB 1 : 2000), goat alexa-fluor 488 anti-rabbit (IF 1 : 400), goat alexa-
fluor 488 anti-mouse (IF 1 : 400); donkey alexa-fluor 488 anti-mouse (IF 1 : 400);
donkey alexa-fluor 647 anti-mouse (IF 1 : 400), donkey alexa-fluor 488 anti-rabbit
(IF 1 : 400), donkey alexa-fluor 647 anti-rabbit (IF 1 : 400); goat biotinylated anti-
mouse IgG (Vector Laboratories, IHC 1 : 250); goat biotinylated anti-rabbit IgG (Vector
Laboratories, IHC 1 : 250).
Immunoblotting. For whole-cell extracts, cells were lysed in urea buffer
containing 8 M urea, 1 M thiourea, 0.5% 3-[(3-cholamidopropyl)dimethylammonio]-2-
hydroxy-1-propanesulfonate, 50 mM dithiothreitol and 24 mM spermine. Nuclear and
cytoplasmic extract fractions were prepared from 5 × 105 cells using a nuclei
isolation kit (NUC101-1KT, Sigma-Aldrich, UK) according to the manufacturer’s
instructions and the fractions were then directly dissolved in urea buffer. After
centrifugation the supernatant was dissolved in SDS loading buffer prior to
immunoblot analysis. A total of 100 μg of protein extract was loaded per lane into
SDS-polyacrylamide gels. Gels were transferred onto nitrocellulose membrane
(Protran, Sigma-Aldrich) and the resulting blots incubated first with primary antibody
for 16 h at 4 °C, and then with the appropriate HRP-conjugated secondary antibody
(Dako). Protein expression was visualised by enhanced chemiluminescent detection
(Amersham Biosciences, Little Chalfont, UK) using X-ray film. All autoradiographs
were scanned using a photo scanner. For the detection of specific iASPP isoforms
extracts were immunoblotted on a 16 × 12 cm 6% gel. The antibody used for iASPP
immunoblotting was LX49.341 unless otherwise stated.
Immunocytochemistry. Cells grown to 70–80% confluence on coverslips
were fixed with 4% paraformaldehyde solution, permeabilised with 0.1% Triton X
solution, blocked with 0.2% BSA and primary antibody was added for 1 h at room
temperature. Secondary antibody and 4′,6-diamidino-2-phenylindole (DAPI) was
then added and coverslips were mounted with mowiol-glycerol solution.
Immunoprecipitation. Cells grown on 15 cm dishes were washed with cold
PBS and lysed with 100 mM NaCl, 1 mM ethylenediaminetetraacetic acid (EDTA),
20 mM Tris (NET) 1% NP-40 IP buffer containing protease inhibitors. Cell lysates
were centrifuged at 13 200 r.p.m., 4 °C, for 20 min, and the protein concentration of
the supernatant determined. Fifty microlitres of each lysate was used as an input
control. Protein G sepharose beads were washed in cold PBS, made up to a ratio of
1 : 1 with PBS and stored at 4 °C. Each lysate was pre-cleared using 30 μl of slurry
beads and rotation for 60 min at 4 °C, and then lysates were centrifuged at 4 °C. Ten
microlitres of antibody was added to the supernatant along with 30 μl of fresh
protein G sepharose beads and the sample rotated overnight at 4 °C. Beads were
washed in NET IP buffer and 0.2% NP-40 before being centrifuged further. The
supernatant was then removed and sample buffer added to the beads. Samples
were then boiled, centrifuged and sample buffer added.
Human tissue samples. TMA sections were obtained from the Department
of Urology, University of Bern, Switzerland. Following IHC protein expression,
scores for each core were assigned by a histopathologist (FF and VS). Pathologic
tumour stage 3 (pT3) PCa whole-mount sections were obtained from the Oxford
Centre for Histopathology Research, Nuffield Division of Clinical Laboratory
Sciences, University of Oxford, Oxford Radcliffe Hospitals National Health Service
(NHS) Trust, Oxford, UK. After IHC protein expression scores for different areas of
interest were assigned by a histopathologist (CV). This study had ethics committee
approval (reference number 09/H0606/78).
IHC and IF. Sections were de-paraffinised in histoclear and rehydrated through
graded alcohols to water. Endogenous peroxidise activity was inactivated where
appropriate using 3% H2O2 in methanol, and where necessary antigen retrieval was
performed using boiling citric acid (human tissue, TP63) or EDTA (mouse tissue,
TP63 and iASPP) buffers. Sections were blocked with 5% normal goat serum and
incubated with primary antibody at 4 °C overnight. For IHC, a biotinylated secondary
antibody was added for 30 min followed by an avidin/biotin-based peroxidase
solution and incubated with 3,3′-diaminobenzidine solution before counterstaining
with haematoxylin. For IF, an appropriate secondary antibody with DAPI was added
for 1 h. All sections were dehydrated using increasing percentages of ethanol
followed by histoclear and mounted in mowiol-glycerol medium. The sections
were viewed and photographed with a confocal (IF) or light (IHC) microscope.
Where described H&E and Alcian blue staining, were performed using standard
techniques.
Tissue apoptosis assay. Apoptotic cells were detected using an ApopTag
Red In Situ Apoptosis Detection Kit (Merck Millipore, Watford, UK) according to
the manufacturer’s recommended protocol.
Quantification of prostate lobe size and protein expression in
mouse and human prostate tissue studies. The size of the prostate
ventral and dorsolateral lobes was measured based on the assumption that that
they are elliptical in shape. Four microlitre sections were cut through the entire
prostate and every tenth section stained using H&E. The largest surface area of
each lobe section was calculated using Image J software (NIH Image, Bethesda,
MD, USA), and the volume of each lobe calculated using the depth of each lobe
(taken from the number of sections available) using the equation: lobe
volume= (4/3) × π × r1 × r2 × r3 (where r1= height, r2=width, r3= depth).
All cell counts in mouse prostate tissue studies were performed using a minimum
of 1000 cells. Four fields of view at × 20 magnification per slide were randomly
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selected for each prostate lobe. Three different slides were used per analysis and per
animal. Analysis was performed using Image J software (NIH Image).
iASPP expression intensity in human tissue samples was scored by a
histopathologist (CV, FF, VS). The maximum iASPP expression within each TMA
core was recorded. Nuclear expression was graded as absent (0), weak (1),
moderate (2) or strong (3). Cytoplasmic expression was graded as absent (0), weak
(1) or strong (2). iASPP expression in cells invading the prostatic capsule, or within
intra-prostatic tumour, along with benign prostate epithelium in pT3 PCa whole-mount
sections was scored in a similar manner by a histopathologist (CV).
Statistical methods and patient survival analysis. Patient survival
analysis was performed by Kaplan–Meier analysis using a log rank test and SPSS
statistics 20 software (IBM, Portsmouth, UK). Paired and unpaired t-tests, and
Mann–Whitney U-tests, were performed using GraphPad Prism (GraphPad, La
Jolla, CA, USA) or excel software. All statistical tests were performed as two-tailed
tests. Differences were considered significant at a P-valueo0.05. All error bars
shown on figures are S.E.M.
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